Neoplasms Pancreatic
19
3
5
7
Key Insights
Highlights
Success Rate
64% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
21.1%
4 terminated out of 19 trials
63.6%
-22.9% vs benchmark
0%
0 trials in Phase 3/4
43%
3 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (19)
ImmunoPET Imaging of Pancreatic Cancer
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer
Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
9-ING-41 in Patients with Advanced Cancers
PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer
Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer
The Effect of Cannabis in Pancreatic Cancer
Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement
A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma
PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer
A Pilot Study of BXCL701 in Patients With Pancreatic Cancer
Percutaneous Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer
Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer
First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors
Gemcitabine and CT-011 for Resected Pancreatic Cancer
Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer